Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week.
J Am Coll Cardiol
; 74(13): 1714-1727, 2019 10 01.
Article
en En
| MEDLINE
| ID: mdl-31558256
ABSTRACT
Immune checkpoint inhibitors (ICIs) have been an important therapeutic advance in the field of cancer medicine, resulting in a significant improvement in survival of patients with advanced malignancies. Recent reports provided greater insights into the incidence of cardiovascular adverse events (CVAEs) with ICI use. Myocarditis is the most common CVAE associated with ICI. Pericardial diseases, Takotsubo syndrome, arrhythmias, and vasculitis constitute other significant AEs. Physicians should be aware of these infrequent, but potentially fatal toxicities associated with ICIs as their therapeutic use becomes widespread with a myriad of approvals by the U.S. Food and Drug Administration. Management involves prompt administration of high-dose corticosteroids and discontinuation of ICIs in severe myocarditis. This review summarizes the most updated evidence on epidemiology, pathophysiological mechanisms, and management strategies of various CVAEs associated with ICIs. Highlights from recent guidelines published by National Comprehensive Cancer Network on ICI-related CV toxicities have also been incorporated.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
6_ODS3_enfermedades_notrasmisibles
Problema de salud:
6_cardiovascular_diseases
Asunto principal:
Cardiología
/
Enfermedades Cardiovasculares
/
Cardiotoxinas
/
Antineoplásicos Inmunológicos
/
Factores Inmunológicos
Tipo de estudio:
Clinical_trials
/
Guideline
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
J Am Coll Cardiol
Año:
2019
Tipo del documento:
Article